The American College of Cardiology (ACC) has published its “2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient with Cardiac Amyloidosis” in the Journal of the American College of Cardiology.
December 22, 2020
Clinicians have a new tool to help them in deciding how best to balance risks and benefits when there’s a need to mix anticoagulation and antiplatelet therapy in patients with A-fib or venous thromboembolism (VTE). It comes in the form of an expert consensus decision pathway from the American College of Cardiology (ACC).
“In general, we have recommended against routine use of triple therapy, which would be [dual antiplatelet therapy (DAPT)] plus anticoagulation,” Dharam Kumbhani, MD (UT Southwestern Medical Center, Dallas, TX), chair of the writing committee, told TCTMD.
Double therapy is the way to go for most cases “based on the concordance of all the data that’s available,” he said, “and several meta-analyses that have looked at that and provided that conclusion.” There are some scenarios when a patient has a high thrombotic risk and low bleeding risk, for example for which physicians may opt for triple therapy for a short duration, Kumbhani no